Correlation of cytokine levels and response to radiation therapy and/or brachytherapy in low/intermediate risk prostate cancer.

被引：0
|
作者：
Ashamalla, H
Marella, V
Feliberti, J
Kavosh, E
Guirguis, A
Fahim, O
Wise, G
机构：
[1] NY Methodist Hosp, Brooklyn, NY USA
[2] Maimonides Hosp, Brooklyn, NY 11219 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：190S / 190S
页数：1
相关论文
共 50 条
  • [41] Ten year treatment outcomes of radical prostatectomy vs external beam radiation therapy vs brachytherapy for 1,503 patients with intermediate risk prostate cancer.
    Goy, Barry W.
    Burchette, Raoul J.
    Soper, Margaret Swenson
    Chang, Tangel C.
    Cosmatos, Harry A.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [42] Overview of the radiobiology of prostate cancer. Implication for clinical research and radiotherapy (external radiation therapy and brachytherapy)
    Cartei, F
    Princivalle, S
    Lavagnini, P
    Api, L
    Tura, A
    TUMORI, 2001, 87 (04) : S132 - S133
  • [43] A comparative analysis between low-dose-rate brachytherapy and external beam radiation therapy for low- and intermediate-risk prostate cancer in Asian men
    Li, Youquan
    Ngai, Thomas Chan Kong
    Zhou, Siqin
    Hwong, Jerome Yap Haw
    Ping, Eric Pang Pei
    Li Kuan, Ashley Ong
    Chek, Michael Wang Lian
    Kiang, Melvin Chua Lee
    Looi, Wen Shen
    Nei, Wen Long
    Chua, Eu Tiong
    On, Weber Lau Kam
    Kiat, Terence Tan Wee
    Peng, John Yuen Shyi
    Loong, Jeffrey Tuan Kit
    ACTA ONCOLOGICA, 2021, 60 (10) : 1291 - 1295
  • [44] DIFFERENT PSA KINETICS AFTER BRACHYTHERAPY OR EXTERNAL BEAM RADIATION THERAPY IN LOW-RISK PROSTATE CANCER
    Guarneri, Alessia
    Botticella, Angela
    Ruggieri, Andrea
    Munoz, Fernando
    Ragona, Riccardo
    Filippi, Andrea Riccardo
    Ricardi, Umberto
    ANTICANCER RESEARCH, 2012, 32 (05) : 1915 - 1916
  • [45] STEROTACTIC BODY RADIATION THERAPY FOR LOW AND INTERMEDIATE RISK PROSTATE CANCER: 3 FRACTIONS HYPOFRACTIONATED SCHEDULE
    Farneti, Alessia
    Landoni, Valeria
    Petrongari, Maria Grazia
    Saracino, Biancamaria
    Faiella, Adriana
    Iaccarino, Giuseppe
    Soriani, Antonella
    Ferriero, Marilia
    Gallucci, Michele
    Sanguineti, Giuseppe
    ANTICANCER RESEARCH, 2018, 38 (04) : 2545 - 2546
  • [46] Determinants of the Combined Use of External Beam Radiation Therapy and Brachytherapy for Low-Risk Localized Prostate Cancer
    Quek, R. G. W.
    Master, V. A.
    Ward, K. C.
    Lin, C. C.
    Virgo, K. S.
    Portier, K. M.
    Lipscomb, J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2013, 87 (02): : S484 - S485
  • [47] Morbidity and prostate-specific antigen control of external beam radiation therapy plus low-dose-rate brachytherapy boost for low, intermediate, and high-risk prostate cancer
    Koontz, Bridget F.
    Chino, Junzo
    Lee, W. Robert
    Hahn, Carol A.
    Buckley, Niall
    Huang, Samuel
    Kim, Jay
    Reagan, Robert
    Joyner, Raymond
    Anscher, Mitchell S.
    BRACHYTHERAPY, 2009, 8 (02) : 191 - 196
  • [48] Lack of Benefit From the Addition of External Beam Radiation Therapy to Brachytherapy for Intermediate- and High-risk Prostate Cancer
    Yang, David D.
    Muralidhar, Vinayak
    Nguyen, Paul L.
    Buzurovic, Ivan
    Martin, Neil E.
    Mouw, Kent W.
    Devlin, Phillip M.
    Quoc-Dien Trinh
    Orio, Peter F., III
    King, Martin T.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 99 (04): : 904 - 911
  • [49] Survival of Low-Risk and Intermediate-Risk Prostate Cancer Patients Treated with IMRT Or Brachytherapy
    Podder, T.
    Dey, A.
    Datta, S.
    Biswas, T.
    MEDICAL PHYSICS, 2020, 47 (06) : E318 - E318
  • [50] Low toxicity of focal low-dose-rate (LDR) brachytherapy for intermediate risk prostate cancer
    Harkin, Timothy
    Smyth, Lloyd
    Anderson, Elliot
    O'Sullivan, Richard
    Ryan, Andrew
    Lawrentschuk, Nathan
    Katz, Darren
    Grummet, Jeremy
    See, Andrew
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2023, 19 : 76 - 76
12345